<DOC>
	<DOCNO>NCT00644176</DOCNO>
	<brief_summary>The objective trial characterize pharmacokinetics currently market azithromycin immediate release tablet formulation ( AZ-IR ) versus azithromycin sustain release liquid formulation ( AZ-SR ) lung tissue bronchial washing , latter consist epithelial lining fluid ( ELF ) cellular element , mainly alveolar macrophage ( AM ) .</brief_summary>
	<brief_title>A Randomized , Open Label , Clinical Trial Pharmacokinetics Azithromycin Following Single Dose Azithromycin Sustained Release ( 2 Gram ) Commercial Azithromycin Tablet ( 500 mg ) Cancer Patients That Require Lung Surgery</brief_title>
	<detailed_description />
	<mesh_term>Azithromycin</mesh_term>
	<criteria>Inclusion criterion hospitalize subject diagnose lung cancer consent surgery require lung resection life expectancy &gt; 6 month . Key exclusion criterion antibiotic prophylaxis prior surgery , diffuse , noninfectious lung disease , history cigarette smoke &gt; 5 pack per year , patient infectious disease require antibiotic therapy , administration drug know interfere azithromycin pharmacokinetics , subject chemotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>